Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · Real-Time Price · USD
15.15
-0.22 (-1.43%)
At close: Aug 14, 2026, 4:00 PM EDT
15.00
-0.15 (-0.99%)
After-hours: Aug 14, 2026, 7:34 PM EDT
Q32 Bio Revenue
In the year 2025, Q32 Bio had annual revenue of $53.74M.
Revenue (ttm)
$53.74M
Revenue Growth
n/a
P/S Ratio
8.39
Revenue / Employee
$2,442,591
Employees
22
Market Cap
451.01M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.74M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | -6.65M | -9.86M | - |
| Dec 31, 2022 | 3.21M | -30.76M | -90.56% |
| Dec 31, 2021 | 33.97M | 31.27M | 1,157.25% |
| Dec 31, 2020 | 2.70M | 1.04M | 62.18% |
| Dec 31, 2019 | 1.67M | -3.66M | -68.70% |
| Dec 31, 2018 | 5.32M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 231.24M |
| Prothena Corporation | 54.53M |
| Editas Medicine | 47.01M |
| Capricor Therapeutics | 11.13M |
| Ocugen | 4.58M |
| SL Science Holding | 3.27M |
| Inhibikase Therapeutics | 1.00 |
QTTB News
- 10 days ago - Q32 Bio Quarterly report: Q2 2026 - Filings
- 10 days ago - Q32 Bio Earnings release: Q2 2026 - Filings
- 10 days ago - Q32 Bio Slides: Corporate presentation - Filings
- 10 days ago - Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 18 days ago - Q32 Bio price target raised to $36 from $13 at H.C. Wainwright - TheFly
- 4 weeks ago - Q32 Bio files to sell 6.88M shares of common stock for holders - TheFly
- 4 weeks ago - Q32 Bio Registration statement: Registration filing - Filings
- 4 weeks ago - Q32 Bio 6.03M share secondary priced at $18.25 - TheFly